Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:32:32.280Z.
Calculation as of: 2026-10-06T16:32:32.280Z.
Quote observation: 2026-10-06T16:30:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b98ba4015092d5f9d3a8f7230bb6a5b98cf1bb4c669b9b66f04bb37649ead8fd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2025-08-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$64.41M
EV/FCF Ratio
N/A
TTM Avg
1.41x
3Y Avg
1.41x
5Y Avg
1.41x
Market Cap
$63.78M
EV/FCF Ratio
N/A
TTM Avg
41.03x
3Y Avg
41.03x
5Y Avg
41.03x
Market Cap
$60.79M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | $64.41M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.41M | N/A | 1.41x | 1.41x | 1.41x |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | N/A | 41.03x | 41.03x | 41.03x |
| InterCure Ltd. (INCR)vs › | $63.02M | 14.40x | 12.61x | 12.61x | 118.68x |
| Cingulate Inc. (CING)vs › | $65.80M | N/A | N/A | N/A | N/A |
| RenovoRx, Inc. (RNXT)vs › | $65.33M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.34M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.79M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.69M | N/A | 108.20x | 108.20x | 108.20x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2025-08-05 | 73.06x |
| 2025-08-04 | 73.31x |
| 2025-08-01 | 69.07x |
| 2025-07-31 | 70.07x |
| 2025-07-30 | 71.06x |
| 2025-07-29 | 68.07x |
| 2025-07-28 | 68.57x |
| 2025-07-25 | 65.07x |
| 2025-07-24 | 63.57x |
| 2025-07-23 | 65.82x |
| 2025-07-22 | 62.08x |
| 2025-07-21 | 62.82x |
| 2025-07-18 | 61.58x |
| 2025-07-17 | 61.83x |
| 2025-07-16 | 60.58x |
| 2025-07-15 | 55.33x |
| 2025-07-14 | 57.33x |
| 2025-07-11 | 53.09x |
| 2025-07-10 | 53.09x |
| 2025-07-09 | 53.09x |
| 2025-07-08 | 50.84x |
| 2025-07-07 | 50.34x |
| 2025-07-03 | 50.09x |
| 2025-07-02 | 49.34x |
| 2025-07-01 | 50.34x |
| 2025-06-30 | 49.84x |
| 2025-06-27 | 50.34x |
| 2025-06-26 | 51.59x |
| 2025-06-25 | 53.09x |
| 2025-06-24 | 53.59x |
| 2025-06-23 | 53.34x |
| 2025-06-20 | 55.08x |
| 2025-06-18 | 51.34x |
| 2025-06-17 | 50.09x |
| 2025-06-16 | 51.09x |
| 2025-06-13 | 50.09x |
| 2025-06-12 | 50.84x |
| 2025-06-11 | 51.34x |
| 2025-06-10 | 50.34x |
| 2025-06-09 | 52.34x |
| 2025-06-06 | 52.34x |
| 2025-06-05 | 50.59x |
| 2025-06-04 | 50.59x |
| 2025-06-03 | 49.59x |
| 2025-06-02 | 48.09x |
| 2025-05-30 | 46.84x |
| 2025-05-29 | 47.34x |
| 2025-05-28 | 48.09x |
| 2025-05-27 | 47.09x |
| 2025-05-23 | 49.09x |
| 2025-05-22 | 48.09x |
| 2025-05-21 | 47.84x |
| 2025-05-20 | 48.59x |
| 2025-05-19 | 46.34x |
| 2025-05-16 | 45.10x |
